​

Benitec Biopharma Stock (NASDAQ:BNTC)

ForecastOwnershipFinancialsChart
Benitec Biopharma by TradingView

Previous Close

$15.06

52W Range

$9.10 - $17.15

50D Avg

$13.40

200D Avg

$13.01

Market Cap

$417.38M

Avg Vol (3M)

$53.77K

Beta

0.41

Div Yield

-

BNTC Company Profile

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

16

IPO Date

Jun 24, 2014

Website

BNTC Performance

BNTC Financial Summary

Jun 25Jun 24Jun 23
Revenue-$216.00K$75.00K
Operating Income$-41.77M$-22.49M$-19.08M
Net Income$-37.92M$-21.75M$-19.56M
EBITDA$-41.77M$-21.41M$-19.15M
Basic EPS$-1.05$-2.68$-14.12
Diluted EPS$-1.05$-2.68$-14.12

Fiscal year ends in Jun 25 | Currency in USD

Latest Earnings Call Transcripts

Q3 18Jun 01, 18 | 5:00 PM

Peer Comparison

TickerCompany
DSGNDesign Therapeutics, Inc.
HUMAHumacyte, Inc.
RAPTRAPT Therapeutics, Inc.
DMACDiaMedica Therapeutics Inc.
DBVTDBV Technologies S.A.
CLLSCellectis S.A.
AMRNAmarin Corporation plc
AURAAura Biosciences, Inc.
KRROKorro Bio, Inc.